Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-cash Items: 2014-2024

Historic Non-cash Items for Zevra Therapeutics (ZVRA) over the last 9 years, with Dec 2024 value amounting to $2.4 million.

  • Zevra Therapeutics' Non-cash Items fell 78.36% to $2.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.4 million, marking a year-over-year decrease of 78.36%. This contributed to the annual value of $2.4 million for FY2024, which is 78.36% down from last year.
  • Latest data reveals that Zevra Therapeutics reported Non-cash Items of $2.4 million as of FY2024, which was down 78.36% from $11.1 million recorded in FY2023.
  • Over the past 5 years, Zevra Therapeutics' Non-cash Items peaked at $11.8 million during FY2022, and registered a low of $307,215 during FY2021.
  • Moreover, its 3-year median value for Non-cash Items was $11.1 million (2023), whereas its average is $8.4 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Non-cash Items skyrocketed by 3,747.14% in 2022, and later crashed by 78.36% in 2024.
  • Yearly analysis of 5 years shows Zevra Therapeutics' Non-cash Items stood at $543,021 in 2020, then slumped by 43.42% to $307,215 in 2021, then surged by 3,747.14% to $11.8 million in 2022, then decreased by 6.18% to $11.1 million in 2023, then slumped by 78.36% to $2.4 million in 2024.